At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 130 enrolled
Drug / intervention
Protamine fixed dose +1 moredrug
Likely dose
Protamine fixed dose 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Optimal Protamine Dosing for Heparin Reversal Following Cardiopulmonary Bypass: A Blinded Randomized Control Trial Comparing Two Strategies
In Brief
A Phase 4 clinical trial evaluating Protamine fixed dose and Protamine ratio dose for Coagulation; Intravascular. Completed, enrolled 130 participants across 2 sites.
Detailed Summary
The purpose of this study is to compare two different dosing strategies of a drug named protamine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoagulation; Intravascular
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2023202420252026
First PostedJun 2022
Enrollment StartJun 2022
Primary CompletionJun 2023
TodayJul 2026
First PostedJun 21, 2022
Enrollment StartJun 28, 2022
Primary CompletionJun 1, 2023
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 4.0 years ago
Interventions
Protamine fixed dosedrug
250 mg of protamine intravenously (IV), one time use
Protamine ratio dosedrug
1mg of protamine per 100 units of heparin given intravenously (IV), one time use